p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
暂无分享,去创建一个
Anita Langerød | Magali Olivier | Pierre Hainaut | A. Langerød | M. Olivier | P. Hainaut | Suresh Anaganti | L. Fernandez-Cuesta | Suresh Anaganti | Lynnette Fernández-Cuesta
[1] S. Hanks,et al. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases , 1995, Molecular and cellular biology.
[2] S. Jhanwar,et al. Hormonal regulation of tumor suppressor proteins in breast cancer cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[3] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[4] F. Kittrell,et al. Hormone dependence in premalignant mammary progression. , 2003, Cancer research.
[5] D. Schlaepfer,et al. Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.
[6] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] J. Depasquale,et al. Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[8] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[9] B. van de Water,et al. Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.
[10] V. Golubovskaya,et al. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. , 2004, Biochimica et biophysica acta.
[11] Neil O. Carragher,et al. The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.
[12] P. Hainaut,et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB , 2006, Oncogene.
[13] Bei Wang,et al. Redefining the p53 response element , 2009, Proceedings of the National Academy of Sciences.
[14] M. Planas-Silva,et al. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. , 2006, Biochemical and biophysical research communications.
[15] W. Muller,et al. Multifaceted Roles of Integrins in Breast Cancer Metastasis , 2007, Journal of Mammary Gland Biology and Neoplasia.
[16] P. Hainaut,et al. 25 years of p53 research , 2005 .
[17] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[18] S. Grant,et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. , 2004, Genes & development.
[19] Joseph Geradts,et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype , 2005, Modern Pathology.
[20] Hongjuan Zhao,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.
[21] M. Olivier,et al. Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines , 2010, Breast Cancer Research and Treatment.
[22] V. Golubovskaya,et al. p53 regulates FAK expression in human tumor cells , 2008, Molecular carcinogenesis.
[23] Francesca Storici,et al. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.
[24] F. Wright,et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] W. Cance,et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. , 1995, Cancer research.
[26] C. Turner,et al. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly , 1992, The Journal of cell biology.
[27] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.
[28] A. Børresen-Dale,et al. Prognostic and Predictive Value of TP53 Mutations in Human Cancer , 2007 .
[29] P. Conte,et al. The curability of breast cancer and the treatment of advanced disease , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[30] S. Conrad,et al. c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells* , 2005, Journal of Biological Chemistry.
[31] Bob van de Water,et al. Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.
[32] R. Eeles,et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.
[33] R. Millikan,et al. FAK overexpression and p53 mutations are highly correlated in human breast cancer , 2009, International journal of cancer.